FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:1057-1059 October 4, 2001 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by de Lemos, J. A. Related Article by Bayes-Genis, A. PubMed Citation

The acute coronary syndromes, which comprise unstable angina, myocardial infarction without ST-segment elevation, and myocardial infarction with ST-segment elevation, continue to be a major health problem. Recent important advances in revascularization techniques, such as the advent of coronary-artery stenting, have been paralleled by developments in drug treatment. A typical approach to the acute coronary syndromes includes multiple treatment options: aspirin, beta-blockers, nitrates, unfractionated heparin, low-molecular-weight heparin, intravenous glycoprotein IIb/IIIa receptor inhibitors, clopidogrel, coronary stenting, thrombolytic agents, statins, and angiotensin-converting–enzyme (ACE) inhibitors. Therefore, one of the most important challenges in this era of cost containment is to identify the subgroup of . . . [Full Text of this Article]

References

This article has been cited by other articles:

• NACB WRITING GROUP MEMBERS, , Morrow, D. A., Cannon, C. P., Jesse, R. L., Newby, L. K., Ravkilde, J., Storrow, A. B., Wu, A. H.B., Christenson, R. H. (2007). National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes. Circulation 115: e356-e375 [Full Text]  
• NACB WRITING GROUP MEMBERS, , Morrow, D. A., Cannon, C. P., Jesse, R. L., Newby, L. K., Ravkilde, J., Storrow, A. B., Wu, A. H.B., Christenson, R. H., NACB COMMITTEE MEMBERS, , Christenson, R. H., Apple, F. S., Cannon, C. P., Francis, G., Jesse, R. L., Morrow, D. A., Newby, L. K., Ravkilde, J., Storrow, A. B., Tang, W., Wu, A. H.B. (2007). National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes. Clin. Chem. 53: 552-574 [Full Text]  
• Panteghini, M. (2004). Role and importance of biochemical markers in clinical cardiology. Eur Heart J 25: 1187-1196 [Abstract] [Full Text]  
• de Denus, S., Pharand, C., Williamson, D. R. (2004). Brain Natriuretic Peptide in the Management of Heart Failure: The Versatile Neurohormone. Chest 125: 652-668 [Abstract] [Full Text]  
• Beciani, M., Tedesco, A., Violante, A., Cipriani, S., Azzarito, M., Sturniolo, A., Splendiani, G. (2003). Cardiac troponin I (2nd generation assay) in chronic haemodialysis patients: prevalence and prognostic value. Nephrol Dial Transplant 18: 942-946 [Abstract] [Full Text]  
• Futterman, L. G., Lemberg, L. (2002). Novel Markers in the Acute Coronary Syndrome: BNP, IL-6, PAPP-A. Am J Crit Care 11: 168-172 [Full Text]  
• (2001). PAPP-A Predicts Outcomes in ACS Patients. Journal Watch Cardiology 2001: 6-6 [Full Text]